Netris Pharma was founded by the pioneers of Dependence Receptors and its mission is to provide cancer patients with new treatment solutions able to overcome resistance to chemo- and Immunotherapies.

The company is currently developing NP137, a first-in-class monoclonal antibody targeting Netrin1, a new untapped oncology target aberrantly expressed in multiple tumor types. Netrin1 has been showed to promote Epithelial-Mesenchymal Transition (EMT) and by disrupting the binding of Netrin1 to its receptors, NP137 is arguably the first compound able to break the deadlock of EMT to reduce metastasis and block resistance to cancer treatment. The product benefits from an excellent safety profile in monotherapy and in combination, and has already shown signs of antitumoral activity. In particular, the LAPNET study of NP137 in combination with mFolfirinox in Pancreatic cancer patients revealed neogenin as a potential predictive biomarker and opened a path for a biomarker-driven development in PDAC. Beyond PDAC, interim efficacy data in HNSCC and HCC further illustrate the potential of the product across solid tumors and strengthen the committment to advance NP137 as a new treatment option to address patient populations with high unmet medical need.

In order to leverage the full potential of anti Netrin-1 therapeutics, Netris Pharma is also investigating the potential of NP137 in Endometriosis. Indeed, consistent with its role in EMT, Netrin1 expression has been documented in endometriosis lesions and the company generated exciting preclinical data on reduction of disease progression, inflammation, fibrosis and related pain symptoms that could lead to the first non-hormonal disease-modifier for this vastly underserved indication.

Companies involved in the development of therapeutic antibodies (as well as other therapeutic proteins) need to choose and develop the right lead as early as possible in order to avoid either technical or IP deadlocks, and to ensure that they are heading in the optimal direction. In addition, it is necessary to file the broadest possible patents as quickly as possible.

Deeptope’s offer consists in characterizing antigen/antibody interactions (epitope/paratope mapping) and optimizing antibodies. The company can also work on many other protein-protein interactions and corresponding protein optimizations.

Their methodology is based on the use of high-throughput in vitro mutagenesis data.
In the context of therapeutic protein development, Deeptope provides:

– Epitope mapping:
• Equally reliable data whether the epitope is conformational or linear
• Economies of scale, with the possibility to use the same antigen mono-mutant library for several antibodies
• A short time frame (4 to 6 weeks)

– Paratope mapping:
• In vitro functional data
• Accuracy to the nearest amino acid
• Comprehensive, reliable, robust and reproducible results
• Prediction of cross-reactivity and selectivity
• A short time frame (4 to 6 weeks)

– Optimization:
• A 360° screening, via the identification of all mutations of interest
• A simultaneous, multi-parametric process that allows the identification of an optimized sequence as well as the associated family of variants (IP protection)
• Fast (4 to 6 weeks), definitive and comprehensive results

Thanks to its services, Deeptope’s clients optimize development costs by derisking their programs at the best cost/duration ratio:

1) Through the evaluation of a large number of leads to choose one according to criteria specific to the biology of the target, freedom to operate, cross-reactivity, selectivity, and other factors

2) By obtaining an optimized lead ready for clinical trials and reinforcing antibody patentability by describing the epitope and paratope and protecting a sequence and a family of associated variants

Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple therapeutic areas. Its innovative treatments are designed to ensure adherence to medical prescriptions, enhance the effectiveness and accessibility of medicines, and reduce their environmental impact.

These treatments combine active pharmaceutical ingredients with Medincell’s proprietary BEPO® / BEPO® Star technologies, which enable controlled drug delivery at therapeutic levels for several days, weeks, or months following a subcutaneous or local injection of a small, fully bioresorbable depot.

Risperidone LAI was the first treatment based on BEPO® technology to receive FDA approval, initially for schizophrenia in April 2023, and subsequently for Bipolar I Disorder in October 2025. It is marketed in the United States by Teva under the brand name UZEDY®. Medincell’s risperidone LAI was also approved for schizophrenia in Canada and South Korea in 2025.

A New Drug Application (NDA) for Olanzapine LAI as a once-monthly treatment for schizophrenia in adults was submitted to the U.S. FDA in December 2025 by Medincell’s partner, Teva. The U.S. FDA accepted Teva’s NDA for Olanzapine LAI on February 20, 2026.

Medincell’s investigational pipeline includes numerous innovative therapeutic candidates in various stages of development, from formulation to Phase 3 clinical trials. Medincell collaborates with leading pharmaceutical companies and foundations to advance global health through new treatment options.

Headquartered in Montpellier, France, Medincell employs over 140 people representing more than 25 nationalities.

UZEDY® is a trademark of Teva Pharmaceuticals. Medincell’s BEPO® technology is licensed to Teva as SteadyTeq™, a trademark of Teva Pharmaceuticals.

Lys Therapeutics is a late preclinical-stage biotechnology company developing first-in-class monoclonal antibodies to treat patients suffering from severe neurodegenerative and neurovascular diseases with high unmet medical needs. The company targets upstream disease biology common to multiple major neurological indications, at the intersection of neurovascular dysfunction, neuroinflammation, and excitotoxicity.

Its lead candidate, LYS241, is a fully humanized monoclonal antibody with a unique mode of action that selectively blocks the pathological interaction between tissue plasminogen activator (tPA) and NMDAr, while preserving normal receptor function. By uncoupling this key neurovascular axis, LYS241 simultaneously restores blood-brain barrier integrity, reduces neuroinflammation, and protects both vascular and neuronal compartments.

With operations in Lyon and Caen (France) and strong collaborations with leading international academic institutions, Lys Therapeutics is advancing a pipeline-in-a-drug strategy centered on LYS241. The company is supported by prestigious partners including The Michael J. Fox Foundation, Bpifrance, and leading private investors.

By targeting a unifying neurovascular mechanism, Lys Therapeutics aims to develop disease-modifying therapies capable of transforming outcomes across a broad spectrum of neurological diseases.

AUROBAC THERAPEUTICS is a biopharmaceutical company established in 2022 through a strategic partnership between three global leaders in life sciences innovation: Boehringer Ingelheim, Evotec and bioMérieux. AUROBAC is dedicated to tackling urgent and unmet medical needs in the treatment of bacterial infections and their consequences in acute hospital settings, with a strong focus on the escalating threat of antimicrobial resistance (AMR).

AUROBAC is advancing a robust and diversified pipeline, headlined by ATX101, a potential first-in-class host-targeted therapy in development for the treatment of sepsis and septic shock (Phase 2 in preparation).

In parallel, AUROBAC has established multiple strategic partnerships to build a robust drug discovery engine designed to identify novel antimicrobial agents. This innovative platform aims to accelerate the development of novel treatments for acute respiratory infections, such as Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP) caused by Gram-negative pathogens.

Affilogic is a private biotech company specialized in discovering and developing affinity proteins, Nanofitins®, through early-stage collaborations with worldwide industry leaders in the pharmaceutical sector.

Each Nanofitin® is 20 times smaller than an antibody and hyperstable. Nanofitins® are easily combined by simple, rapid, and proven methods to design an ideal targeted molecule.

Affilogic is investing internally in 4 programs that leverage the core advantages of Nanofitins®:

1 – Bus2Brain: Enhanced brain uptake of biologics to reignite CNS therapies
2 – Respitude: Inhaled antiviral Nanofitin® therapeutics against respiratory infections
3 – GI Job: Targeting GI tract diseases by oral administration
4 – ODC: Small-size Nanofitin®-drug conjugates against solid tumors with a new therapeutic window

Moreover, with NanoVector, Affilogic is partnering with third parties to deliver their therapeutic compounds to specific cells/organs (ASO, siRNA, nanoparticles, antibodies, enzymes, peptides, CAR-T, AAV…).

Such programs illustrate the versatility of Nanofitins®, designed as APIs or as vectors for the specific transport of therapeutic molecules, administered systemically, via the oral route for a local effect in the GI tract, or via direct pulmonary delivery.

Exeliom Biosciences is a clinical-stage immunotherapy company developing a first-in-class oral innate immune modulator designed to enhance the efficacy and durability of immune checkpoint inhibitors (ICIs). Its lead asset, EXL01, selectively activates the non-canonical NOD2–CARD9 signaling axis, reprogramming tumor-associated macrophages from an immunosuppressive to an antigen-presenting, T-cell–supportive state.

By restoring upstream myeloid competence, EXL01 addresses a central bottleneck in immuno-oncology: resistance driven by dysfunctional innate immunity. Preclinical and translational data demonstrate enhanced interferon signaling, improved antigen presentation, and deeper, more durable ICI responses without triggering systemic inflammation.

EXL01 is currently being evaluated in a randomized Phase II trial in first-line advanced gastric cancer in combination with nivolumab and chemotherapy. Additional expansion studies are ongoing in renal cell carcinoma, hepatocellular carcinoma, and NSCLC, across Europe and the United States.

Beyond oncology, EXL01 is being developed in other indications, including Crohn’s disease, and infectious disease, where preliminary clinical efficacy signals have been observed.

With patent protection through 2044, a scalable GMP manufacturing platform, and a clear registrational pathway in oncology, Exeliom Biosciences offers partners a differentiated, first-in-class strategy to extend and defend ICI franchises in a post–patent cliff landscape.